This review concluded that cannabis treatment was moderately efficacious for the treatment of chronic pain, but the risk of potentially serious harms may offset any treatment benefit. The authors' conclusion reflected the evidence presented, but the extent to which it is reliable is potentially compromised by an incompletely reported review process and reliance on trials of less than optimal quality.
Study selection
Double-blind, randomised controlled trials (RCTs) of any cannabis preparations (synthetic or otherwise; administered by any route) that minimally contained delta-9-tetrahydrocannabinol, were eligible for inclusion in the review. The control group was required to receive a placebo treatment. Eligible participants were those suffering pathologically-or traumatically-induced constant or intermittent chronic pain, for a minimum of six months.
The outcomes of interest were pain intensity measured by numeric analogue scales, and the number of adverse events.
Over half of the included trials evaluated more than one cannabis intervention arm (various preparations or doses of the same preparation) compared with placebo. One trial was excluded because it assessed smoked cannabis. Trial differences were also noted in terms of type and aetiology of chronic pain. All included patients had chronic pain of a continuous or intermittent nature, and there was comparable baseline pain intensity amongst the intervention groups. Where reported, the mean age of participants ranged from 39 to 63 years; 46 to 95% were female.
The authors did not state how many reviewers selected the studies.
Assessment of study quality
Trial quality was assessed using the Jadad scale, covering randomisation, allocation concealment, withdrawals, and dropouts. A score of 5 points indicated the highest quality.
Two independent reviewers performed the quality assessment.
Data extraction
For intervention efficacy, data were extracted on initial and final means with standard deviations (SD) to enable the calculation of standardised mean differences (SMDs) for each trial.
For harms, the number of adverse events was extracted to enable the calculation of odds ratios (OR) and 95% confidence intervals (CI). The number needed to harm (NNH) was also reported. Authors were contacted for additional information, where necessary.
